Cell Envelope Biogenesis in Mycobacterium tuberculosis

Information

  • Research Project
  • 10239074
  • ApplicationId
    10239074
  • Core Project Number
    R01AI141513
  • Full Project Number
    5R01AI141513-04
  • Serial Number
    141513
  • FOA Number
    PA-18-484
  • Sub Project Id
  • Project Start Date
    9/14/2018 - 7 years ago
  • Project End Date
    8/31/2023 - 2 years ago
  • Program Officer Name
    MENDEZ, SUSANA
  • Budget Start Date
    9/1/2021 - 4 years ago
  • Budget End Date
    8/31/2022 - 3 years ago
  • Fiscal Year
    2021
  • Support Year
    04
  • Suffix
  • Award Notice Date
    8/27/2021 - 4 years ago

Cell Envelope Biogenesis in Mycobacterium tuberculosis

Project Summary To eradicate tuberculosis (TB), the World Health Organization has proposed reducing TB-related deaths from >1 million to just 50,000 per year by 2025. This 95% reduction will not be met by current programs. Thus, the strategic plan to eliminate TB emphasizes the development of new drugs against the causative bacterium, Mycobacterium tuberculosis (Mtb). The Mtb cell envelope has thus been the target of many efforts to find novel anti-TB therapeutics. However, discovery and validation of new targets is hampered by our limited understanding how the cell envelope is made. Enzymes that make mycomembrane lipids have been characterized, but the mechanism of subsequent lipid incorporation into the mycomembrane remains poorly defined. We and others have identified a pathway that is required for both the transport and the synthesis of diverse mycomembrane lipids. Based on our published work and preliminary data, we hypothesize that the lipoprotein LprG and membrane protein Rv1410c play a broad role in mycomembrane biogenesis by mediating a crucial step in transporting lipids beyond the cytoplasmic membrane and into the mycomembrane. To test this model, we will pursue the following aims: (1) Determine how LprG and Rv1410c regulate lipid transport to the mycomembrane and (2) Determine how LprG-Rv1410c regulates the addition of mycolic acid-bearing virulence factors to the mycomembrane. Our innovation is to test a novel model for mycomembrane biogenesis and to do so we will leverage our expertise in mycobacteriology and lipid biochemistry to achieve our long-term goal of understanding lipid transport processes that enable the mycomembrane to form and contribute to virulence. The successful completion of these Specific Aims will provide important advances in our understanding of a virulence-associated pathway that mediates these processes in the Mtb cell envelope.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R01
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
    225000
  • Indirect Cost Amount
    133875
  • Total Cost
    358875
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    NIAID:358875\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    BACP
  • Study Section Name
    Bacterial Pathogenesis Study Section
  • Organization Name
    STATE UNIVERSITY NEW YORK STONY BROOK
  • Organization Department
    PHARMACOLOGY
  • Organization DUNS
    804878247
  • Organization City
    STONY BROOK
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    117943362
  • Organization District
    UNITED STATES